<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We recently demonstrated that the cysteine proteinase inhibitor, <z:chebi fb="0" ids="30270">E-64</z:chebi>, sensitizes human Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Daudi) to the antitumor action of <z:chebi fb="0" ids="3139">bleomycin</z:chebi> (BLM) by blocking its metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>We now report that <z:chebi fb="0" ids="30270">E-64</z:chebi> sensitizes the BLM resistant human <z:mp ids='MP_0008714'>lung carcinoma</z:mp> A-549 by a mechanism unrelated to the inhibition of BLM metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment of A-549 tumor-bearing <z:mp ids='MP_0003815'>nude</z:mp> mice with either BLM (10 mg/kg) or <z:chebi fb="0" ids="30270">E-64</z:chebi> (40 mg/kg) every other day for 10 days did not inhibit <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, a 30 min pretreatment with <z:chebi fb="0" ids="30270">E-64</z:chebi> prior to BLM caused complete and sustained inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast to our results with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:chebi fb="0" ids="30270">E-64</z:chebi> did not inhibit BLM metabolism but rather enhanced the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> accumulation of BLM; within 10 min of BLM administration, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from <z:chebi fb="0" ids="30270">E-64</z:chebi> pretreated mice showed a 6-fold higher accumulation of BLM A2 compared to non-pretreated xenografts </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, the level of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated BLM A2 remained 2-fold higher in <z:chebi fb="0" ids="30270">E-64</z:chebi> pretreated mice 20 and 30 min after BLM administration </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:chebi fb="0" ids="30270">E-64</z:chebi> pretreated mice, the plasma level of BLM was increased by 2-fold </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that the cysteine proteinase inhibitor, <z:chebi fb="0" ids="30270">E-64</z:chebi>, sensitized human <z:mp ids='MP_0008714'>lung carcinoma</z:mp> A-549 to BLM and, contrary to the expected mechanism, this effect of <z:chebi fb="0" ids="30270">E-64</z:chebi> was not related to the inhibition of BLM metabolism </plain></SENT>
</text></document>